For a new device, the Director General of the Agence nationale de sécurité du médicament et des produits de santé may, at any time and for a period of two years following the declaration provided for in Article R. 5221-35, ask the manufacturer or his authorised representative to provide a report on the experience acquired with this device after it has been placed on the market.